Patients

Lab companies have been booking record profits by charging $100 per test.

“Because somebody is making money and somebody is losing money, and I can't figure out who’s who.”

Unable to fly out under lockdown, Zimbabwe’s wealthy must now take their chances in local hospitals alongside everyone else.

Now the 28-year-old has been told her “last option” is a treatment that costs $12,000 every three weeks.

In the narrow window in which patients are aware of their disease, they have sought help in clinical trials. But enrolling enough participants to make these trials count is not easy.

NICE does not have a role in drug pricing. The charge for the medication is based on cost price and mark-up – as is usual in retail – plus a dispensing fee, which can vary depending on the NHS trust.

Edward was diagnosed at seven weeks with spinal muscular atrophy. His parents are begging authorities for him to get a £1.7m wonder drug.

eople living with amyotrophic lateral sclerosis, or ALS, in the U.S. will have to wait longer than their counterparts in Europe and Canada for access to a potentially beneficial treatment, even though the medicine is being developed here.

We need to expand the pinpoints of empathy to which medical fund-raisers appeal.

Southern cancer patients paying for unfunded drugs say they are doing so because they are desperate.

Americans suffering from the condition are running into financial problems due to the inconsistent nature of the U.S. health-care system.

About 1 in 5 U.S. adults have skipped healthcare over the past year because they couldn't afford it.

Ayah was diagnosed with spinal muscular atrophy, a genetic disease found in one in 10,000 children born worldwide.

The drug is not covered under B.C. PharmaCare and she says Pacific Blue Cross denied her coverage request.

CNBC's Meg Tirell joins ‘The News with Shepard Smith’ to report on one mother who is seeking help from an experimental drug to treat her terminal illness.